STOCKCHASE

Half of business in Pharma space and rest is in nutritional area.

2011-10-24

BUY

54.050

Restructuring came as a big surprise. Good valuation at 10X earnings. Long track record of raising dividends. Only real competition is Johnson & Johnson (JNJ-N) but feels this one has better growth. If they do the spinoff, they will probably stick with the non-pharma side of the business, which will be the better growth.

2011-10-20

HOLD

53.250

Stan Wong

The market likes the split. Going to split into pharma and medical space. 3.6% dividend. Hold on to it for the time being.

2011-10-19

BUY

50.920

Diversified Pharma with pharmaceuticals, nutritionals and medical devices. Trading at a lower valuation (11X earnings) with a higher dividend and better growth prospects than Johnson & Johnson (JNJ-N).

2011-09-14

BUY

21.270

Have grown earnings every single year since 1991. Only 10 or 11x earnings. Likes them in the health care space because they are diversified. Market is worried about their largest drug, whose patent expires in a few years. He doesn’t see it as a problem.

2011-08-31

PAST TOP PICK

50.200

(A Top Pick July 26/10. Up 5.72%.) Diversified healthcare company. Branded drug division has Marot for arthritis etc., medical devices including stents and nutritional. Have also been making acquisitions in the branded generic space. Good diversity. About 20% of revenues come from emerging markets.

2011-08-02

DON'T BUY

53.330

Brian Acker, CA

He has a model price of $57.97, an 8% upside. Good company but he sees a lot of value elsewhere.

2011-07-08

BUY

53.330

Raised dividend 30+ years in a row. Is going to show 10% earnings growth over next 2-3 years. A good space. They got too cheap so there is an opportunity.

2011-05-24

TOP PICK

52.850

All different types of health care services and products. 11 times this year’s earnings. Nice valuation and entry point here.

2011-05-03

PAST TOP PICK

52.590

(A Top Pick April 26/10. Up 8.35%.) Have both generic and branded drug divisions. Making acquisitions to increase their emerging market exposure, which currently represent 25% of their revenues. Also has the number one share in the drug alluding stent business. Very strong nutritional business.

2011-05-02

BUY

52.180

Only a part of their business is in the pharma. Biggest drug is Humera for rheumatoid arthritis, which doesn’t go off patent until 2016. Also have a strong nutritional business. Earnings have grown every single year since 1991. Trades at about 11X earnings. Almost 4% dividend.

2011-04-27

BUY

46.710

Likes it. Patent on Humera goes off in 2016. 20 years in a row they increased earnings per share. Reasonable multiple. They are not getting the benefit of the doubt for the good work they are doing internationally. The health care sector is out of favour. Steadily increase the dividend.

2011-03-16

HOLD

45.730

Annual succession of increased earnings since 1992 but not getting credit for what they are doing. Trades at about 10X earnings. Health care has been a tough sector to be in. Be patient and let the sector come back into favour and let the street endorse what they are doing. Street is worried about expiration of their major drug Humera but that doesn’t expire until 2016.

2011-02-02

PAST TOP PICK

48.120

Hap (Robert) Sneddon FCSI

(A Top Pick Jan 13/10. Down 10.82%.) Very consistent grower and still likes.

2010-12-15

BUY

46.950

Don Reed

Recently checked back. Well managed and in good financial shape.

2010-11-23

BUY on WEAKNESS

47.400

Good entry point at the support level of around $46. If it corrects and holds at $46, that is pretty powerful. Crummy relative strength, which is a pretty good sign. Do a partial Buy at $46 and another at around $43 and a final one at $41.

2010-11-19

TOP PICK

49.240

Diversified healthcare in the US. Have a branded pharmaceutical business providing drugs for arthritis, cholesterol and prostate cancer. Also had a nutritional business providing babies formula and adults’ nutrition. Also have stents, which is doing quite well globally. Trading at about 10.5X forward earnings. About 3.6% yield and have increased dividends on a regular basis.

2010-07-26

DON'T BUY

47.870

Brian Acker, CA

The model price is $48.13, a 2% upside only. Fully priced.

2010-05-27

BUY

49.150

Have a little less than 50% of their business in pharmaceuticals. Their big drug is Humera for rheumatoid arthritis and doesn't come off patent until 2016. Also have about 20%-25% revenues from their nutritional business.

2010-05-12

TOP PICK

50.370

Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.

2010-04-26

BUY

52.310

Don Lato

Great company with a great pipeline. Humira, a rheumatoid arthritis drug, is their major product is on patent until 2016. Have never had a down year in stock price since 1992.

2010-04-14

Comment

55.350

David Baskin

Not hot on pharmaceuticals because of generic manufacturing and litigation risks. This one is a pretty good choice in pharmaceuticals with a pretty good product line up going forward. A lower risk way to play pharmaceuticals is through Johnson & Johnson (JNJ-N) that has both pharmaceuticals and branded consumer products.

2010-01-14

TOP PICK

55.290

Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.

2010-01-13

BUY

46.310